ArticleTherapeutic innovation & regulatory science2026
Simulation-Calibrated Control of Type I Error Rate in One-Trial Approach with Dose Optimization in Oncology Drug Development.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The one-trial approach [8] has emerged as a pivotal strategy for streamlining oncology drug development by allowing a single study to support both accelerated approval (AA) and regular approval (RA). The integrating Dose Optimization with One-Trial Approach (iDOOTA) framework extends this paradigm by enabling a single randomized study to both identify an optimal biological dose (OBD) and provide confirmatory evidence on short- and long-term clinical outcomes, such as ORR and OS. In this paper, we propose a simulation-based calibration strategy to control the type I error rate induced by dose selection within the iDOOTA framework. A numerical case study is presented to illustrate the key features and practical implementation of the proposed method. In addition, several operational considerations relevant to the iDOOTA framework are discussed. As with all innovative regulatory strategies, it is advisable to seek FDA agreement during the study design phase to ensure alignment and facilitate subsequent regulatory review.
Indexed as
Identifiers
42209905What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.